natgillin/translations-raw huggingface dataset:
These monomers could contain both an amino group and a carboxylic group that in a condensation process eliminate water e.g. 
Ti monomeri mogu sadržavati amino-skupinu i karboksilnu skupinu koja u postupku kondenzacije eliminira vodu, npr.
from about 2 to about 40 nucleotides in length; ii) up to about 100 nucleotides in length; or 
duljine oko 2 do oko 40 nukleotida; ii) do 100 nukleotida; ili iii) više od 100 nukleotida.
represents a phenyl-group, which group is unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and dimethylamino; and R2 represents -CO-CH3. 
R! predstavlja piridil- ili aril-skupinu, gdje je ta skupina nesupstituirana, mono-, di- ili tri-supstituirana, pri čemu su supstituenti neovisno odabrani iz skupine koju čine halogen, (C,-Cy)alkil, (Ci-Cy)alkoksi.
producing a colloidal suspension of said nano-crystalline particles by subjecting the mixture to a milling process in a milling chamber, wherein said mixture is contacted with milling beads, separating said beads from said colloidal suspension. The method preferably involves 
- = proizvodnje koloidne suspenzije navedenih nano-kristaliničnih čestica podvrgavanjem smjese postupku mljevenja u komori za mljevenje (4; 4A: 4B; 4C), pri čemu je navedena smjesa u kontaktu sa zrncima (9) u kugličnom mlinu,
The method according to claim 1, wherein said homotrimer, heterotrimer, homotetramer and/or heterotetramer of the said carbohydrate components are present in liquid or solid phase, whereby said MCFA are present in liquid or solid phase, and wherein the feed supplement is present in liquid or solid phase. 
Dodatak prehrani prema bilo kojem od zahtjeva 1 do 4, gdje se spomenuti homo-trimer, hetero-trimer, homo- tetramer i/ili hetero-tetramer spomenute ugljikohidratne komponente nalaze u tekućoj ili krutoj fazi, gdje se spomenuti MCFA-i nalaze u tekućoj ili krutoj fazi, i gdje se dodatak prehrani nalazi u tekućoj ili krutoj fazi.
The image processing apparatus according to any of claims 1 to 5, wherein the processed image generating device (22) changes a weighting mode in accordance with frequency components of the band image (a,B,Y). 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 5, naznačen time, da uređaj za stvaranje obrađene slike (22) mijenja način opterećenja težinskim faktorom u skladu s frekvencijskim komponentama od slike na traci (o, fB, y).
The expanded, cellular material according to any of the preceding claims which further comprises nucleating agents and fillers. 
Ekspandirani, pjenasti materijal prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se dodatno sastoji od nukleacijskih agensa i punila.
A pyrido(2,3-d)pyrimidine derivative according to any of claims 1 to 11 for use in prevention or treatment of immune disorders, autoimmune disorders, cardiovascular disorders, disorders of the central nervous system, TNF-alpha related disorders and cell proliferative disorders. 
Derivat pirido(2,3-d)pirimidina prema bilo kojem od patentnih zahtjeva 1 do 11 naznačen time što se koristi za primjenu u prevenciji ili liječenju imunih poremećaja, autoimunih poremećaja, kardiovaskularnih poremećaja, poremećaja središnjeg živčanog sustava, poremećaja vezanih za TNF-alfa 1 staničnih proliferativnih poremećaja.
An indolizine derivative as claimed in claim 8 or 9, wherein R1a represents a hydroxy group, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
Derivat indolizina prema zahtjevu 8, gdje R'* predstavlja hidroksi skupinu, ili prolijek, ili farmaceutski prihvatljiva sol.
In one embodiment, the BC loop comprises the underlined portion of SEQ ID NO: 34. 
(viti) glicin na položaju 8 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom S;
The method according to claim 1, wherein the composition further comprises at least one chelating agent selected from ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje kompozicija dalje sadrži najmanje jedan helatni agens odabran od etilen diamintetraoctene kiseline (EDTA) 1 etilen glikol tetraoctene kiseline (EGTA).
The filter assembly for the fluid filter as claimed in claim 2, wherein the extending pipe 23 includes an extending section 231 which protrudes from the top surface 211 of the input plate 21 and is inserted in the inserting hole 31 of the output member 30. 
Sklop filtera prema zahtjevu 1, naznačen time što produžna cijev 23 sadrži produženi dio 231 koji strši iz gornje površine 211 ulazne ploče 21 i ulazi u otvor za umetanje 31 izlaznog elementa 30.
A pharmaceutical combination of Claim 31 wherein the combination of the compound of Claim 1 and the sulfonyl urea is administered in the same or separate oral dosage forms. 
Farmaceutski sastav Zahtjeva 31, naznačen time, da se kombinacija spoja Zahtjeva 1 i sulfonil uree unosi u istim ili odvojenim oblicima oralnih doza.
The receiver according to claim 14, wherein the rim element is flexible as well as compressible so that it can seal well with a minimum of pressure being applied. The receiver according to claim 1, wherein the receiver includes a removable lid. 
Prijemna posuda sukladno patentnom zahtjevu 15, naznačena time što je element okvira fleksibilan kao i to da ga je moguće sabiti tako da omogućava dobru zabrtvljenost uz minimalnu primjenu pritiska.
Pharmaceutical composition comprising a VLP according to any of the above embodiments wherein at least 1%, preferably at least 15%, more preferably at least 50%, in particular preferred at least 95% of the total amount of drug substance (cargo) is fully encapsulated in the hull of the VLP. Pharmaceutical composition according to embodiment 9 wherein the VLP are non-aggregated. 
Farmaceutski pripravak namijenjen uporabi u postupku liječenja terapijom ili metodom in vivo dijagnosticiranja bolesti CNS, dok farmaceutski sastav sadrži VLP prema bilo kojem od gore navedenih zahtjeva, pri čemu najmanje 1%, poželjno najmanje 15%, poželjnije najmanje 50%, naročito poželjno najmanje 95% ukupne količine lijeka potpuno je enkapsulirano u trup VLP-a 13.
The rim block cage according to one of the preceding claims, characterized in that the flushing water distribution element (8) is integral with the containers. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da je element za distribuciju vode za ispiranje (8) oblikovan integralno sa spremnikom ili spremnicima.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
The compound for use according to claim 11, wherein the ALK- or FAK-mediated condition or disorder is selected from: 
Spoj za upotrebu iz patentnog zahtjeva 10, pri čemu je ALK- ili FAK- posredovano stanje ili poremećaj izabrano od:
The host cell according to claim 13, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, myeloma, and lymphoma cells. 
Stanica domaćina prema patentnom zahtjevu 24, gdje je spomenuta stanica domaćina najmanje izabrana iz COS-1, COS-7, HEK293, BHK21, CHO, BSC-I, Hep G2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg derivata, imortalizovanih-besmrtnih ili transformisanih ćelija od njih.
The obtained average value must be equal to the preceding one with a maximum 1 bit difference, otherwise the system jumps to phase II again. 
Postignuta srednja vrijednost mora biti jednaka prethodnoj s najviše 1 bitom razlike, inače se sustav ponovo vraća na fazu II.
Use of a compound according to claim 1 for the manufacture of a medicament for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject having a cardiac condition or for the treatment of a cardiac condition in a subject. 
Uporaba spoja prema patentnom zahtjevu 1, naznačena time što je za proizvodnju lijeka za liječenje ili prevenciju srčanog stanja kod subjekta.
The polyguanidine derivative according to claim 1, wherein the salt is an acid addition salt in a form of a hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfate, carbonate, borate, cyanate, thiocyanate, phosphate, mesylate, nitrate, acetate, benzoate, lactate, tartrate, citrate, maleate, fumarate, a partial ester of one of these acids, in case they are difunctional or higher, or as a mixture of at least two of these salts and/or partial esters. 
Poligvanidinski derivat u skladu s bilo kojim patentnim zahtjevom 1 do 6, naznačen time, da je kisela adicijska sol u obliku hidroklorida, hidrobromida, hidrojodida, sulfata, karbonata, borata, cijanata, tiocijanata, fosfata, mezilata, nitrata, acetata, benzoata, laktata, tartarata, citrata, maleata, fumarata ili djelomičnog estera jedne od ovih kiselina ako su bifunkcionalne ili višefunkcionalne ili mješavina dviju ili više ovih soli 1 / ili djelomičnih estera.
Intermediate of formula (6′) was dissolved in THF and the solution was added with 10 eq of 1M LiOH in water. 
Međuprodukt formule (6') je otopljen u THF i otopina je dodana vodi s 10 ekviv. IM LiOH.
It is stirred at 0 °C for 2 hours, observing the solidification of the reaction crude. 
To se miješa 2 sata pri OC, pri čemu se opaža skrućivanje sirovog proizvoda.
Process according to claim 7 wherein 5 to 70 mol% of said monomers are monomeric salts derived from an organic acid having a first pKa of 2.0 or less and a polymerisable base having a first pKa of the conjugate acid of at least 4.0. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što 5 do 70 molarnih % od navedenih monomera čine monomerne soli koje se dobiva iz organske kiseline čiji je prvi pKa 2,0 ili manji i polimerizabilne baze čiji je prvi pKa konjugirane kiseline najmanje 4,0.
A solid oral dosage form comprising darunavir and a therapeutically effective amount of a citrate salt of the compound of formula I: 
Farmaceutska smjesa koja sadrži terapijski učinkovitu količinu soli ili hidrata prema bilo kojem od zahtjeva 1-14 i farmaceutski prihvatljivi nosač ili pomoćnu tvar.
Method according to claim 6, wherein compound of formula (XXIV) is prepared in three steps, the three steps are a step (Q1), a step (Q2) and a step (Q3); 
Postupak prema zahtjevu 6, naznačen time da spoj formule (XXIV) bude spravljen u tri koraka, pri čemu se radi o tri koraka, korak (Q1), korak (Q2) i korak (Q3);
In a further embodiment the invention also relates to use of a compound of the invention as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of agoraphobia. 
U jednom daljnjem obliku izum se također odnosi na korištenje spoja izuma kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod za liječenje agorafobije.
conjugating a cytotoxic agent to the cell-binding agents having linkers bound thereto in the first mixture by reacting the cell-binding agent having linkers bound thereto with a cytotoxic agent in a solution having a pH of 4 to 9 to prepare a second mixture comprising (i) cell-binding agent chemically coupled through the linker to the cytotoxic agent, (ii) free cytotoxic agent, and (iii) reaction by-products, and 
konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (ii) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, i
A method as claimed in claim 6, wherein the amount of modified starch in the stabiliser composition is 16 to 35% by dry weight. 
Postupak prema patentnom zahijevu 6, naznačen time što je količina modificiranog škroba u kompoziciji stabilizatora 16 do 35% prema suhoj težini.
In addition, the conditions, diseases, and maladies collectively referenced to as “Syndrome X” or Metabolic Syndrome as detailed in Johannsson J. Clin. 
Pored toga, stanja i bolesti zajednički označeni kao "sindrom X" ih metabolički smdrom kao što je detaljno opisano u Johannsson J. Clin.
A method for preparing a compound represented by Formula IV: or an acceptable salt or ester, thereof; 
Tvar Formule III: Formula 11 ili njena farmaceutski prihvatljiva sol ili ester; pri čemu:
detecting the polypeptide and the one or more charge variants. 
detekciju polipeptida i jedne ili više nabijenih varijanti.
The compounds of formula I may exist e.g. in free or salt form. 
Spojevi formule I mogu biti na primjer u slobodnom obliku ili u obliku soli.
The magnesia cement of any one of claims 5 to 11, characterized in that it comprises finely grinded hard-burned, dead-burned, and/or fused magnesia, all of said finely grinded magnesia having an average particle size of less than 60 µm, preferably less than 45 µm, and optionally of from 5 to 25 µm. 
Magnezijski cement prema bilo kojem od zahtjeva 5 do 11, naznačen time što sadrži fino mljevenu tvrdo-pečenu, mrtvo-pečenu, i/ili fuzioniranu magneziju, sve od spomenutih fino mljevenih magnezija imaju prosječnu veličinu čestice manju od 60 µm, poželjno manju od 45 µm i izborno od 5 do 25 µm.
A compound according to claim 7, wherein R1 is aryl, wherein said aryl is unsubstituted or substituted with 1 or 2 substituent(s) R6; 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da R1 je aril, pri čemu je rečeni aril nesupstituiran ili supstituiran s 1 ili 2 supstituenta R6;
This AC voltage is amplified by operational amplifier 90 and provided at its output 90u. 
Taj izmjenični napon se pojačava operacijskim pojačalom 90 i daje na izlazu 90u.
Process for the separation of enantiomers of triazine derivatives of formula (I) below: wherein: 
PATENTNI ZAHTJEVI 1. Postupak za razdvajanje enantiomera derivata triazina s formulom (1) ispod:
Composition of claim 1 for use as a medicament for the treatment of festering wounds, throphic ulcers and burns, infiltrations with marked necrotic and exudative components. 
Sastav prema zahtjevu 1, naznačen time, da služi za uporabu kao lijek za liječenje gnojnih rana, trofičkih čireva i opeklina, infiltracija s naznačenim nekrotičkim i eksudativnim komponentama.
Use according to claim 1 characterized in that the mammals are cats, dogs, or horses. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da su sisavci mačke, psi ili konji.
The compound according to claim 1, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p -toluenesulfonate, sodium, potassium, calcium and ammonium salts; ethylenediamine, ethanolamine, N,N- dialkylenethanolamine, triethanolamine and basic aminoacids salts. 
Sjedinjenje sa formulom I, ili njegova farmaceutski prihvatljiva sol ili estar: Formula I. Sjedinjenje prema patentnom zahtjevu 1, gdje je sol odabrana od hidroklorid, hidrobromid, hidrojodid, sulfat, nitrat, fosfat, acetat, trifluoroacetat, maleat, fumarat, citrat, oksalat, sukcinat, tartrat, malat, mandelat, metansulfonat, p-toluensulfonat, natrij, kalij, kalcij i amonij soli; etilendiamin, etanolamin, N,N-dial_kilen etanolamin, trietanolamin i soli baznih aminokiselina.
Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced, and the amount may be determined from results of the sequencing. 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka obogaćene za sekvence manje od 300 bp.
A closure for a vial or a plunger for a hypodermic syringe according to any one of the preceding claims characterised by an elastomer material having an absorption coefficient in the range 1.0 - 2.5 mm-1. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, što elastomerni materijal ima koeficijent apsorpcije u području od 1.0 - 2.5 mm.
The method according to claim 1, wherein the oxidant is selected from hydrogen peroxide, carbamide peroxide, and benzoyl peroxide. The method according to claim 1, wherein the composition further comprises at least one hydrophilic gelling agent. The method according to claim 6, wherein the hydrophilic gelling agent is selected from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbomer polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
detecting the absence of an insertion in the nucleotide sequence encoding a polypeptide comprising the amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 3 by using molecular marker; 
detektiranju polimorfije kao na Slikama 1, 2 ili 3; ili ii) detektiranju prisutnosti ili odsutnosti insercije u kodirajućem nukleotidnom slijedu molekule nukleinske kiseline u skladu s patentnim zahtjevom 1.
The compound of claim 1, selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time daje odabran iz skupine koju čine
In one aspect, the invention is further related to the use of a compound in treatment or prophylaxis of ischemic stroke, cerebral seizure, thrombosis, embolism, hemorrhage, cardiovascular disease, arthritis, diabetes, cancer, in particular cancer related to aging, atherosclerosis, heart failure, myocardial infarctions, schizophrenia, bipolar disorder, fragile X syndrome, sickle cell disease, and chronic fatigue syndrome, chronic obstructive pulmonary disease (COPD), a neurodegenerative disease such as Alzheimer disease, Parkinson disease, Lou Gehrig's disease, Huntington's disease, hypothermia/reperfusion injury, hemorrhagic shock, aging, hypertension, renal failure due to various kidney diseases, asthma, inflammatory bowel disease, hepatitis and liver cirrhosis, migraine, hyper-homocysteinemia, infection diseases involved in attacking thrombocytes, such as haemorhorragic fever, in particular ebola and chagas wherein the compound has the structural formula of (I) 
(6-hidroksi-2,5,7,8-tetrametilkroman-2-i1)(4-(2-hidroxietil)piperazin-1-ilymetanon, naznačen time, da je u svojem racemičnom ili enantiomernom obliku radi uporabe u svrhu liječenja ili profilakse ishemijskog moždanog udara, celebralnih napada, tromboze, embolizma, krvarenja, kardiovaskularne bolesti, artritisa, dijabetesa, karcinoma, točnije karcinoma vezanog za starenje, ateroskleroze, otkazivanja srca, infarktnih miokarda, shizofrenije, bipolarnog poremećaja, sindroma krhkog X kromosoma, bolesti srpastih stanica, i sindroma kroničnog umora, kronične opstruktivne bolesti pluća (COPD), neurodegenerativne bolesti kao što su Alzheimerova bolest, Parkinsonova bolest, amiotrofična lateralna skleroza, Huntingtonova bolest, hipotermije/reperfuzije, hemoragičnog šoka, infekcijskih bolesti povezanih s napadom ili brzim raspadanjem trombocita, kao na primjer hemororagijska groznica, odnosno ebola, Marburg bolest i Chagasova bolest.
The mouse of any one of claims 1 to 4 and 6, wherein the endogenous heavy and/or λ (lambda) light chain allele do not comprise an endogenous variable gene segment. 
Miš prema zahtjevu 1, naznačen time, što alelu endogenog lakog 2 (lambda) lanca nedostaje endogeni segment gena VA.
The process according to claim 1 wherein the temperature ocillation episode comprises a heating phase and a corresponding cooling phase. 
Postupak prema zahtjevu 1 naznačen time da period temperaturne oscilacije sadrži fazu grijanja i odgovarajuću fazu hlađenja.
means for the detection of methylation of the MAL gene or promoter wherein said means comprise probes, primers specific for MAL or specific for the MAL nucleotide sequence of Figure 1; and 
sredstva za detekiranje metilacije MAL gena ili promotora pri tome navedena sredstva sadrže funkcijske sonde, početnice specifične za MAL ili specifične za MAL sekvencu nukleotida sa Slike 1, i
The rats used for intravenous experiments are also cannulated in the jugular vein (Popovic (1960) J. Appl. 
Stakori koji su rabljeni za intravenozne eksperimente također dobili cjevčicu u jugularnu venu (Popovic (1960) J. Appl.
The retinal derivative for use according to Claim 1, wherein the retinal derivative is a 9- cis -retinyl ester of a C2 to C22 polycarboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester Ci-C19 monokarboksilata.
a centrally located core provided with an upper side and a lower side, 
centralno smještenu jezgru (20, 38) s gornjom stranom (38a) i donjom stranom (38b),
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
R*i R", zajedno sa atomom azota za koji su vezani, obrazuju nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N 1 O;
The method of claim 14, wherein the Crenolanib or a salt thereof is provided as a single agent to at least one of post standard induction therapy, or high dose induction therapy, in newly diagnosed hematologic malignant neoplastic disorder. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u barem jednoj post-standardnoj indukcijskoj terapiji ili indukcijskoj terapiji visoke doze u novodijagnosticiranoj akutnoj mijeloičnoj leukemiji (AML).
The anti-sclerostin antibody for use in the method of claim 1, wherein the treatment period lasts 28 weeks. 
Antisklerostinsko antitijelo za primjenu u načinu prema zahtjevu 1, naznačeno time, što razdoblje liječenja traje 28 tjedana.
the second fragment is a C . difficile toxin B repeating domain fragment; 
drugi fragment je fragment ponavljane domene toksina B i sadrži najmanje 100 aminokiselina;
An antibody comprising an antigen-binding domain and a human FcRn-binding domain, which has a human FcRn-binding activity at pH 5.5 and at pH 7.0 and a lower antigen-binding activity at pH 5.5 than at pH 7.0, wherein the human FcRn-binding domain comprises Leu at amino acid residue position 428 and Ser at amino acid residue position 434 in EU numbering. 
Protutijelo, naznačeno time što sadrži domenu za vezanje na antigen i domenu za vezanje na ljudski FcRn, koja ima aktivnost vezanja na ljudski FcRn kod pH 5,5 i kod pH 7,0 i manju aktivnost vezanja na antigen kod pH 5,5 nego kod pH 7,0, gdje je aktivnost vezanja na ljudski FcRn kod pH 7,0 i na 25 °C veća nego KD 3,2 mM, gdje je domena za vezanje na ljudski FcRn Fc domena dobivena zamjenom različite aminokiselina umjesto najmanje jedne aminokiseline u Fc domeni ljudskog IgG1, IgG2, IgG3 ili IgG4.
An isolated antibody or antibody fragment specific for IL17C for the use of claim 1 or 2 wherein said antibody or fragment thereof is a monoclonal antibody. 
Izolirano antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 1 ili 2, naznačen time, što je navedeno antitijelo ili njegov fragment monoklonsko antitijelo.